Comprehensive Stock Comparison
Compare Corcept Therapeutics Incorporated (CORT) vs Agios Pharmaceuticals, Inc. (AGIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | AGIO | 48.0% revenue growth vs CORT's 12.8% |
| Quality / Margins | CORT | 13.0% net margin vs AGIO's -9.0% |
| Stability / Safety | AGIO | Beta 0.91 vs CORT's 1.12 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | AGIO | -14.9% vs CORT's -41.1% |
| Efficiency (ROA) | CORT | 11.8% ROA vs AGIO's -29.0%, ROIC 6.2% vs -26.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Corcept Therapeutics is a pharmaceutical company focused on developing and commercializing drugs for severe metabolic, oncologic, and neuropsychiatric disorders caused by cortisol excess. It generates revenue primarily from sales of its flagship drug Korlym for Cushing's syndrome, with future growth expected from its pipeline of selective cortisol modulators targeting additional indications. The company's competitive advantage lies in its deep expertise in cortisol modulation and intellectual property around novel glucocorticoid receptor antagonists.
Agios Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases related to cellular metabolism. It generates revenue primarily from sales of its lead drug PYRUKYND for pyruvate kinase deficiency — with additional income from research collaborations and milestone payments — while advancing a pipeline of other metabolic therapies. The company's competitive advantage lies in its deep expertise in cellular metabolism science and proprietary platform for targeting metabolic pathways in rare diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CORT leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). AGIO leads in 2 (Valuation Metrics, Risk & Volatility).
Financial Metrics (TTM)
CORT is the larger business by revenue, generating $761M annually — 17.0x AGIO's $45M. CORT is the more profitable business, keeping 13.0% of every revenue dollar as net income compared to AGIO's -9.0%. On growth, AGIO holds the edge at +43.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CORTCorcept Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $761M | $45M |
| EBITDAEarnings before interest/tax | $47M | -$470M |
| Net IncomeAfter-tax profit | $99M | -$401M |
| Free Cash FlowCash after capex | $142M | -$414M |
| Gross MarginGross profit ÷ Revenue | +98.3% | +84.4% |
| Operating MarginEBIT ÷ Revenue | +5.9% | -10.6% |
| Net MarginNet income ÷ Revenue | +13.0% | -9.0% |
| FCF MarginFCF ÷ Revenue | +18.6% | -9.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +11.1% | +43.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -23.1% | -111.0% |
Valuation Metrics
| Metric | CORTCorcept Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $3.8B | $2.25T |
| Enterprise ValueMkt cap + debt − cash | $3.7B | $2.25T |
| Trailing P/EPrice ÷ TTM EPS | 43.54x | -4.25x |
| Forward P/EPrice ÷ next-FY EPS est. | 97.65x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 78.58x | — |
| Price / SalesMarket cap ÷ Revenue | 4.97x | 9999.00x |
| Price / BookPrice ÷ Book value/share | 6.61x | 1.47x |
| Price / FCFMarket cap ÷ FCF | 26.68x | — |
Profitability & Efficiency
CORT delivers a 15.3% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-31 for AGIO. CORT carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to AGIO's 0.03x. On the Piotroski fundamental quality scale (0–9), CORT scores 5/9 vs AGIO's 3/9, reflecting solid financial health.
| Metric | CORTCorcept Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | +15.3% | -31.2% |
| ROA (TTM)Return on assets | +11.8% | -29.0% |
| ROICReturn on invested capital | +6.2% | -26.6% |
| ROCEReturn on capital employed | +6.5% | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 |
| Debt / EquityFinancial leverage | 0.01x | 0.03x |
| Net DebtTotal debt minus cash | -$114M | -$49M |
| Cash & Equiv.Liquid assets | $120M | $89M |
| Total DebtShort + long-term debt | $6M | $40M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in CORT five years ago would be worth $14,022 today (with dividends reinvested), compared to $6,363 for AGIO. Over the past 12 months, AGIO leads with a -14.9% total return vs CORT's -41.1%. The 3-year compound annual growth rate (CAGR) favors CORT at 19.7% vs AGIO's 6.1% — a key indicator of consistent wealth creation.
| Metric | CORTCorcept Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | -6.5% | +11.2% |
| 1-Year ReturnPast 12 months | -41.1% | -14.9% |
| 3-Year ReturnCumulative with dividends | +71.4% | +19.4% |
| 5-Year ReturnCumulative with dividends | +40.2% | -36.4% |
| 10-Year ReturnCumulative with dividends | +834.6% | -21.2% |
| CAGR (3Y)Annualised 3-year return | +19.7% | +6.1% |
Risk & Volatility
AGIO is the less volatile stock with a 0.91 beta — it tends to amplify market swings less than CORT's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AGIO currently trades 65.7% from its 52-week high vs CORT's 30.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CORTCorcept Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 0.91x |
| 52-Week HighHighest price in past year | $117.33 | $46.00 |
| 52-Week LowLowest price in past year | $28.66 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +30.4% | +65.7% |
| RSI (14)Momentum oscillator 0–100 | 36.5 | 62.3 |
| Avg Volume (50D)Average daily shares traded | 2.3M | 948K |
Analyst Outlook
Wall Street rates CORT as "Buy" and AGIO as "Buy". Consensus price targets imply 91.6% upside for CORT (target: $68) vs 37.3% for AGIO (target: $42).
| Metric | CORTCorcept Therapeut… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $68.40 | $41.50 |
| # AnalystsCovering analysts | 24 | 29 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +6.5% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 100 | 307.94 | +207.9% |
| Agios Pharmaceutica… (AGIO) | 100 | 57.07 | -42.9% |
Corcept Therapeutic… (CORT) returned +40% over 5 years vs Agios Pharmaceutica… (AGIO)'s -36%. A $10,000 investment in CORT 5 years ago would be worth $14,022 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | $81M | $761M | +836.3% |
| Agios Pharmaceutica… (AGIO) | $70M | $54M | -22.7% |
Corcept Therapeutics Incorporated's revenue grew from $81M (2016) to $761M (2025) — a 28.2% CAGR. Agios Pharmaceuticals, Inc.'s revenue grew from $70M (2016) to $54M (2025) — a -2.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 10.0% | 13.1% | +30.8% |
| Agios Pharmaceutica… (AGIO) | -2.8% | -7.6% | -169.0% |
Corcept Therapeutics Incorporated's net margin went from 10% (2016) to 13% (2025). Agios Pharmaceuticals, Inc.'s net margin went from -3% (2016) to -8% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 17.4 | 42.4 | +143.7% |
Corcept Therapeutics Incorporated has traded in a 16x–42x P/E range over 9 years; current trailing P/E is ~44x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 0.07 | 0.82 | +1071.4% |
| Agios Pharmaceutica… (AGIO) | -5.07 | -7.12 | -40.4% |
Corcept Therapeutics Incorporated's EPS grew from $0.07 (2016) to $0.82 (2025) — a 31% CAGR. Agios Pharmaceuticals, Inc.'s EPS grew from $-5.07 (2016) to $-7.12 (2025).
Chart 6Free Cash Flow — 5 Years
Corcept Therapeutics Incorporated generated $142M FCF in 2025 (-15% vs 2021). Agios Pharmaceuticals, Inc. generated $-377M FCF in 2025 (+9% vs 2021).
CORT vs AGIO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CORT or AGIO a better buy right now?
Corcept Therapeutics Incorporated (CORT) offers the better valuation at 43.5x trailing P/E (97.6x forward), making it the more compelling value choice. Analysts rate Corcept Therapeutics Incorporated (CORT) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CORT or AGIO?
Over the past 5 years, Corcept Therapeutics Incorporated (CORT) delivered a total return of +40.2%, compared to -36.4% for Agios Pharmaceuticals, Inc. (AGIO). A $10,000 investment in CORT five years ago would be worth approximately $14K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CORT returned +834.6% versus AGIO's -21.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CORT or AGIO?
By beta (market sensitivity over 5 years), Agios Pharmaceuticals, Inc. (AGIO) is the lower-risk stock at 0.91β versus Corcept Therapeutics Incorporated's 1.12β — meaning CORT is approximately 24% more volatile than AGIO relative to the S&P 500. On balance sheet safety, Corcept Therapeutics Incorporated (CORT) carries a lower debt/equity ratio of 1% versus 3% for Agios Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — CORT or AGIO?
Corcept Therapeutics Incorporated (CORT) is the more profitable company, earning 13.1% net margin versus -764.0% for Agios Pharmaceuticals, Inc. — meaning it keeps 13.1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CORT leads at 5.9% versus -873.9% for AGIO. At the gross margin level — before operating expenses — CORT leads at 98.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is CORT or AGIO more undervalued right now?
Analyst consensus price targets imply the most upside for CORT: 91.6% to $68.40.
06Which pays a better dividend — CORT or AGIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CORT or AGIO better for a retirement portfolio?
For long-horizon retirement investors, Corcept Therapeutics Incorporated (CORT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.12), +834.6% 10Y return). Both have compounded well over 10 years (CORT: +834.6%, AGIO: -21.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CORT and AGIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.